GATC Biotech’s Liquid Biopsy Testing Starts from as Little as EUR 195 Per Sample
GATC Biotech takes also the lead in terms of costs of liquid biopsy testing supporting early implementation of such assays by providing easy technology accessibility to researchers in clinical and translational medicine
23 Mar 2016
GATC Biotech AG, a world-wide leading provider of advanced genome analysis and diagnostic services, has announced the pricing of the company’s liquid biopsy-based services - ONCOEXOME, ONCOPANEL and ONCOTARGET. The prices, released during this week’s 10th International Symposium on Minimal Residual Cancer (ISMRC), start from as little as EUR 195 per sample.
“By adopting this highly competitive pricing strategy, we are responding to the market’s demand for greater accessibility to our liquid biopsy technology. Clinicians can now quickly and accurately characterize cancer so that they can react to this progressive disease in a timely manner,” said Peter Pohl, CEO and co-founder of GATC Biotech.
The three GATCLIQUID services allow highly sensitive detection of genomic alterations in circulating tumor DNA (ctDNA) to capture the entire heterogeneity of cancer. They provide clinical researchers the opportunity to interrogate a whole range of tumor-related mutations that help characterize a patient’s cancer from a simple blood sample.
“As cancer evolves, so must the tools to fight the disease with greater effectiveness,” added Dr Marcus Benz, COO of GATC Biotech. “Due to excellent performance standards, the GATCLIQUID services are poised to play a key role in revolutionizing blood-based cancer research and diagnostics.” By avoiding risk-prone and painful re-biopsies, GATCLIQUID is well-suited for treatment monitoring and therapy decision making in cases of cancer recurrence. ONCOTARGET can be effectively applied to reveal additional therapeutic options for patients with cancer relapse or acquired drug resistance.
“We are proud partners with the oncology community, and this latest move is driven by the desire to facilitate greater physician and patient accessibility to evaluative testing that leads to truly effective treatment. The advantages of liquid biopsy combined with our pricing make GATCLIQUID an ideal tool for monitoring a patient’s cancer at close intervals,” added Peter Pohl.
The GATCLIQUID services are available at the following net prices per sample:
ONCOTARGET for EUR 195 | ONCOPANEL for EUR 1,450 | ONCOEXOME for EUR 2,950
All samples are processed at GATC Biotech’s own laboratories under ISO 17025 accreditation and ISO 13485 certification. GATCLIQUID is applicable to patients with solid tumors, such as lung, skin, breast, intestinal or ovarian cancer.